Fecal immunochemical tests for colorectal cancer screening of average risk individuals: a systematic review of accuracy and compliance

Mujoomdar M, Cimon K, Spry C
Record ID 32010001040
English
Authors' objectives:

To review the evidence on diagnostic accuracy and patient compliance when using fecal immunochemical tests to screen for colorectal cancer.

Authors' recommendations: Fecal immunochemical testing (FIT) may be an effective method to screen for colorectal cancer (CRC) and advanced adenomas, and may be more effective when compared with other screening tests, eg, the guaiac fecal occult blood test (gFOBT). In particular, the HemeSelect, FlexSure OBT, and OC-Sensor Micro FITs demonstrate improved diagnostic performance characteristics compared with gFOBT. All included studies that compared participation rates of FIT with other tests showed that FIT had higher completion rates than the other tests, including gFOBT. Limitations of the included studies should be considered during decision making. Other things to consider when making decisions about the appropriateness of FIT as a screening tool for CRC include the type of FIT to be used, the associated costs, the appropriate hemoglobin cutoff level, and the capacity for follow-up using colonoscopy (CS) or flexible sigmoidoscopy (FS).
Details
Project Status: Completed
URL for project: http://www.cadth.ca/media/pdf/M0010_FIT_for_colorectal_cancer_L3_e.pdf
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Colorectal Neoplasms
  • Indicators and Reagents
  • Predictive Value of Tests
  • Reagent Kits, Diagnostic
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.